255 related articles for article (PubMed ID: 18794097)
1. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
2. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
Soepenberg O; Sparreboom A; de Jonge MJ; Planting AS; de Heus G; Loos WJ; Hartman CM; Bowden C; Verweij J
Eur J Cancer; 2004 Mar; 40(5):681-8. PubMed ID: 15010068
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
7. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
Slingerland M; Guchelaar HJ; Rosing H; Scheulen ME; van Warmerdam LJ; Beijnen JH; Gelderblom H
Clin Ther; 2013 Dec; 35(12):1946-54. PubMed ID: 24290734
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
11. [A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Teng XY; Guan ZZ; Yao ZW; Liu DG; Zhou NN; Luo HY; Hawkins M; Soon-Shiong P
Ai Zheng; 2004 Nov; 23(11 Suppl):1431-6. PubMed ID: 15566651
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Nyman DW; Campbell KJ; Hersh E; Long K; Richardson K; Trieu V; Desai N; Hawkins MJ; Von Hoff DD
J Clin Oncol; 2005 Nov; 23(31):7785-93. PubMed ID: 16258082
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
Lv F; Cao J; Zhang J; Qian J; Peng W; Sun S; Li W; Zhang W; Guo W; Li J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1173-9. PubMed ID: 24658629
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
20. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]